Oxford BioTherapeutics makes US appointments
This article was originally published in Scrip
Executive Summary
Oxford BioTherapeutics (UK) has made several key appointments at its US subsidiary R&D facility near San Jose: Dr Jim Cornett joins as chief operating officer following many years' mAb industry experience at several companies, including Medarex, PDL and Centocor; and Dr Jon Terrett joins as vice-president of oncology, having previously spent several years at Medarex (which was recently acquired by BMS), where he gained experience in the development of oncology biologics. They will work alongside Dr Mike Gresser, who has recently taken over the role of chief scientific officer after working on the company's scientific advisory board since 2007. The US team will focus on developing Oxford BioTherapeutics' antibody programmes.
You may also be interested in...
Morgan Lewis expands FDA & healthcare practice
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma appoints new member to board
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
Optimer expands management team
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.